These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32142738)

  • 1. Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells.
    Rolle F; Bincoletto V; Gazzano E; Rolando B; Lollo G; Stella B; Riganti C; Arpicco S
    Int J Pharm; 2020 Apr; 580():119191. PubMed ID: 32142738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
    Shen Q; Qiu L
    J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance.
    Zhong XC; Shi MH; Liu HN; Chen JJ; Wang TT; Lin MT; Zhang ZT; Zhou Y; Lu YY; Xu WH; Gao JQ; Xu DH; Han M; Chen YD
    Pharm Dev Technol; 2021 Jan; 26(1):21-29. PubMed ID: 33070673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
    Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
    Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of stealth liposome coencapsulating doxorubicin and fluoxetine.
    Ong JC; Sun F; Chan E
    J Liposome Res; 2011 Dec; 21(4):261-71. PubMed ID: 21226547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
    Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
    ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme/pH dual stimuli-responsive nanoplatform co-deliver disulfiram and doxorubicin for effective treatment of breast cancer lung metastasis.
    Xiao P; Tao X; Wang H; Liu H; Feng Y; Zhu Y; Jiang Z; Yin T; Zhang Y; He H; Gou J; Tang X
    Expert Opin Drug Deliv; 2023; 20(7):1015-1031. PubMed ID: 37452715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
    Li Y; Luo J; Lin MT; Zhi P; Guo WW; Han M; You J; Gao JQ
    Mol Pharm; 2019 Jul; 16(7):2966-2979. PubMed ID: 31095914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
    Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
    Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
    Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
    Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
    Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.